Impaired Hepatic Function Clinical Trial
Official title:
A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impaired Hepatic Function and Healthy Subjects
This is a multi-center, open-label clinical study to assess the single-dose PK of eravacycline in subjects with hepatic impairment and healthy subjects conducted at approximately 3 sites in the United States. This study includes an up to 21-day Screening Period, a 5-day Treatment Period, and an End of Study Visit occurring approximately 2 weeks (± 2 days) after initiation of study drug administration. Approximately 24 subjects will be enrolled: 18 subjects with impaired hepatic function (6 subjects who meet the criteria for each of the 3 Child-Pugh categories of mild [5 - 6 points], moderate [7 - 9 points], and severe [10 - 15 points]) and 6 healthy subjects without hepatic impairment. Healthy subjects will be matched to hepatically impaired subjects in gender, age, and body mass index (BMI). All subjects will be administered a single IV dose of eravacycline (1.5 mg/kg).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04136444 -
A Pharmacokinetic Study of Padsevonil in Study Participants With Either Normal or Moderately Impaired Hepatic Function
|
Phase 1 | |
| Completed |
NCT02388620 -
Evaluation of Hepatic Function Impairment on the Pharmacokinetics of LEE011
|
Phase 1 | |
| Completed |
NCT01764776 -
Effect of Hepatic Impairment on LDE225..
|
Phase 1 | |
| Completed |
NCT01950481 -
Effect of Hepatic Impairment on LDK378 Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT00398424 -
Evaluating Patients With Impaired Hepatic Function
|
Phase 1 | |
| Recruiting |
NCT05259085 -
Study of ALXN2050 in Participants With Hepatic Impairment
|
Phase 1 | |
| Completed |
NCT04823702 -
Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function
|
Phase 1 |